4,4'-bipyridyl has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Fang, M; Gao, G; Li, J; Li, M; Li, X; Qian, Y; Qiu, Y; Wang, L; Wang, X; Wu, T | 1 |
1 other study(ies) available for 4,4'-bipyridyl and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin T; Cyclin-Dependent Kinase 9; Humans; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Triple Negative Breast Neoplasms | 2023 |